Devgen drug candidates may promise breakthrough in the treatment of rheumatoid arthritis and other inflammatory diseases
A key competitive edge of the Devgen molecules is that they are small molecule drugs that can be orally administered. The current treatments are protein based therapeutics, applied by injection and are costly to produce. Hence, they are infrequently administered early in the development of the disease.
"Finding orally active TNFa inhibitors is a 'holy grail' in inflammation research as it may provide patients with convenient, cost effective and hence earlier treatment options in the development of these progressive diseases" says Devgen CEO Thierry Bogaert. "Such inhibitors may furthermore be suitable for treating other inflammatory diseases including inflammatory bowel disease and multiple sclerosis".
Devgen is progressing with the development of its novel inhibitors in additional preclinical models of inflammatory diseases and will conduct further studies to complete a preclinical and partnering package over the next 9 months.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.